TYK Medicines, Inc. Class H (HK:2410) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
TYK Medicines, Inc. has reported an increased total comprehensive loss of 26.3% for the first half of 2024 compared to the same period last year, with significant rises in research and development costs and administrative expenses. The company’s losses per share also grew from RMB 0.60 to RMB 0.68, indicating a challenging period for the firm.
For further insights into HK:2410 stock, check out TipRanks’ Stock Analysis page.